Oral etoposide (VP16) in platinum-resistant epithelial ovarian cancer (EOC)

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 26, Issue 4, 2003, Pages 358-362

  Alici, Süleyman ^a   Saip, Pinar ^b   Eralp, Yeşim ^b   Aydiner, Adnan ^b   Topuz, Erkan ^b  

^a YUZUNCU YIL UNIVERSITY   (Turkey)

^b NONE

Author keywords

Oral etoposide; Ovarian cancer; Platinum resistant

Indexed keywords

CARBOPLATIN; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOXORUBICIN; ETOPOSIDE; PACLITAXEL; PLATINUM;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; INFECTION; MUCOSA INFLAMMATION; NEUTROPENIA; OVARY CARCINOMA; PHASE 2 CLINICAL TRIAL; SEPSIS; SIDE EFFECT; THROMBOCYTOPENIA; WORLD HEALTH ORGANIZATION;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CA-125 ANTIGEN; CISPLATIN; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PLATINUM COMPOUNDS; REMISSION INDUCTION; SURVIVAL ANALYSIS;

EID: 0041561252     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200308000-00010     Document Type: Article

References (23)

1. Hoskins PJ, O'Reilly SE, Swenerton KD, et al. Ten-year outcome of patients with advanced epithelial ovarian carcinoma treated with cisplatin-based multimodality therapy. J Clin Oncol 1992;10:1561-8.
2. The Ovarian Cancer Meta-analysis project. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. J Clin Oncol 1991;9:1668-74.
3. Hakes TB, Daghestani AN, Dougherty JB, et al. Phase II study of 4-demethoxydaunorubicin in advanced ovarian carcinoma. Cancer Treat Rep 1985;69:559-60.
4. Sutton GP, Blessing JA, Homesley HD, et al. Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 1989;7:1672-6.
5. Belinson JL, Pretorius RG, McClure M, et al. Hexamethylmelamine, methotrexate, 5-fluorouracil as second-line chemotherapy after platinum for epithelial ovarian malignancies. Gynecol Oncol 1986;23:304-9.
6. Benedeti-Panici P, Scambia G, Greggi S, et al. Doxorubicin and cyclophosphamide alternated with bleomycin and mitomycin C as a second-line regimen in advanced ovarian cancer resistant to cisplatin-based chemotherapy. Oncology 1990;47:296-8.
7. Einzig AI, Wiernik PH, Sasloff J, et al. Phase II study and long term follow-up of patients treated with Taxol for advanced ovarian adenocarcinoma. J Clin Oncol 1992;10:1748-53.
8. Trimple EL, Adams JD, Vena D, et al. Taxol in patients with platinum-resistant ovarian cancer. Proc Am Soc Clin Oncol 1993; 12:261.
9. Slevin ML, Clark SP, Joel S, et al. A randomised trial to evaluate the effect of schedule on the activity of etoposide in small cell lung cancer. J Clin Oncol 1989;7:1333-40.
10. Hainsworth JD, Johnson DH, Frazier SR, et al. Chronic daily administration of oral etoposide-A phase I trial. J Clin Oncol 1989;7:396-401.
11. Johnson DH, Greco FA, Strupp J, et al. Prolonged administration of oral etoposide in patients with relapsed or refractory small cell lung cancer: a phase II trial. J Clin Oncol 1990;8:1613-7.
12. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981;47:207-14.
13. Ozols RE. Treatment of recurrent ovarian cancer: increasing options "recurrent" results. J Clin Oncol 1997;15:2177-80.
14. Kuhnle H, Meerpohl HG, Lenaz L, et al. Etoposide in cisplatin-refractory ovarian cancer. Proc Am Soc Clin Oncol 1988;7:137.
15. Garrow GC, Hainsworth JD, Johnson DH, et al. Prolonged administration of oral etoposide in previously treated epithelial ovarian cancer. A phase II trial. Proc Am Soc Clin Oncol 1992;11:236.
16. Markman M, Hakes T, Reichman B, et al. Phase II trial of chronic low-dose oral etoposide as salvage therapy of platinum-refractory ovarian cancer. J Cancer Res Clin Oncol 1992;119:55-7.
17. Rose PG, Blessing JA, Mayer AR, et al. Prolonged oral etoposide as second line therapy for platinum resistant and platinum sensitive ovarian carcinoma: a Gynecologic Oncology Group study. Proc Am Clin Oncol 1996;15:282.
18. Rose PG, Blessing JA, Mayer AR, et al. Prolonged oral etoposide as second line therapy for platinum resistant and platinum sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1998;16:405-10.
19. Harvey VJ, Slevin ML, Joel SP, et al. Variable bioavailability following repeated oral doses of etoposide. Eur J Cancer Clin Oncol 1985;21:1315-9.
20. Slevin ML. Low dose oral etoposide: a new role for an old drug? [Editorial]. J Clin Oncol 1990;8:1607-9.
21. Joel SP, Dolega-Ossowski E, Jones K, et al. The biovailability of oral etoposide during prolonged oral administration and development of a limited sampling strategy for the estimation of AUC after an oral dose. Proc Am Assoc Cancer Res 1991;32:178.
22. Kavanagh JJ, Morris M, Smalldone L, et al. A randomized trial of carboplatin versus variably timed continuous infusion etoposide in refractory epithelial ovarian cancer. Proc Am Soc Clin Oncol 1989;8:163.
23. Hansen F, Malthe I, Krog H. Phase II clinical trial of etoposide administered orally in advanced ovarian cancer. Gynecol Oncol 1990;36:369-70.